Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial

Abstract Background Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally. Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its current recommended dose is based on no...

Full description

Bibliographic Details
Main Authors: D. Molina-Morant, M. L. Fernández, P. Bosch-Nicolau, E. Sulleiro, M. Bangher, F. Salvador, A. Sanchez-Montalva, A. L. P. Ribeiro, A. M. B. de Paula, S. Eloi, R. Correa-Oliveira, J. C. Villar, S. Sosa-Estani, I. Molina
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Trials
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13063-020-4226-2